Physalaemin: Amphibian Tachykinin Undecapeptide and NK1 Receptor Agonist — Pharmacology Research Reagent

# Physalaemin: A Classic Amphibian Tachykinin and NK1 Receptor Agonist

> Research Use Only (RUO) (PMID: 24387161). Physalaemin and related tachykinin (PMID: 7169058, PMID: 6294828) peptides are described here strictly as laboratory research reagents for in-vitro and biochemical study. Nothing below is a human, veterinary, clinical, diagnostic, or therapeutic claim, and no dosing guidance is implied. Handle as a research chemical under appropriate institutional safety practices.

Physalaemin is one of the foundational peptides of comparative pharmacology — an 11-residue amphibian tachykinin first isolated from the skin of South American Physalaemus frogs during the classic surveys of bioactive amphibian-skin peptides. It belongs to the same tachykinin family as mammalian substance P, shares the family's signature C-terminal motif, and acts as a potent agonist at the NK1 receptor. For researchers, physalaemin remains a benchmark non-mammalian tachykinin (PMID: 7169058, PMID: 6294828) and a long-standing pharmacological tool.

The tachykinin (PMID: 7169058, PMID: 6294828) family and physalaemin's place in it

Tachykinins are defined by a conserved C-terminal sequence, Phe-Xaa-Gly-Leu-Met-NH₂, which is the principal determinant of receptor binding and the rapid ("tachy-") smooth-muscle contraction that gave the family its name. The authoritative review of the tachykinin peptide family places mammalian substance P, neurokinin A, and neurokinin B alongside a rich set of non-mammalian members — including physalaemin, kassinin, and eledoisin — that have been indispensable in mapping receptor pharmacology Pharmacol Rev, 2002. Physalaemin carries the conserved C-terminal pentapeptide amide but differs from substance P in its N-terminal residues, giving it a distinct potency and selectivity profile while remaining strongly NK1-preferring.

Amphibian skin proved to be an extraordinarily productive source of these peptides. Surveys of frog-skin secretions identified physalaemin- and bombesin-like peptides across multiple species, establishing physalaemin as a representative of a widely distributed structural class rather than a single oddity Chem Pharm Bull (Tokyo), 1980. It sits naturally beside the other amphibian-skin research peptides such as the bradykinin homologue maximakinin.

Discovery and historical significance

Physalaemin emerged from the mid-twentieth-century investigation of amphibian skin as a chemical arsenal — a research program that revealed dozens of bioactive peptides with mammalian counterparts or entirely novel pharmacology. Physalaemin became a touchstone of that effort because it was both potent and structurally informative: it demonstrated that the tachykinin (PMID: 7169058, PMID: 6294828) blueprint underlying mammalian substance P was conserved far outside mammals, and it provided a more readily obtainable, robust agonist for receptor work at a time when mammalian tachykinins were scarce. That historical role is why physalaemin appears throughout the foundational tachykinin pharmacology literature and remains a named reference compound in modern reviews Pharmacol Rev, 2002. Its co-occurrence with bombesin-family peptides in the same secretions also helped establish frog skin as a systematic source of receptor-targeted research reagents Chem Pharm Bull (Tokyo), 1980.

Structure and conformation

Physalaemin's solution conformation has been studied across several decades. Early conformational analysis characterized the peptide's preferred backbone geometry Eur J Biochem, 1984, and later nuclear-magnetic-resonance work resolved its solution conformation in lipid micelles, modelling how the non-mammalian tachykinin (PMID: 7169058, PMID: 6294828) orients at a membrane interface en route to its receptor Biopolymers, 2011. The membrane-associated conformation is mechanistically important: like many peptide-GPCR ligands, physalaemin is thought to partition onto the lipid bilayer before presenting its conserved C-terminus to the receptor.

Receptor pharmacology: an NK1 benchmark

Physalaemin's high affinity for the substance P (NK1) receptor made it valuable as a radioligand. Tritiated physalaemin, [³H]physalaemin, was used to specifically label and characterize substance P receptors in rat brain, providing one of the early quantitative handles on central NK1 binding sites J Neurosci, 1985. For researchers, this established physalaemin as a reference agonist for NK1 receptor assays — a role it still plays in comparative tachykinin (PMID: 7169058, PMID: 6294828) studies alongside substance P.

Because the two peptides share the receptor-engaging C-terminus but differ at the N-terminus, physalaemin is a clean comparator for probing how non-conserved residues tune NK1 affinity and signalling.

Documented bioactivity in research models

Across the experimental literature, physalaemin displays the broad spectrum of effects characteristic of NK1-active tachykinins:

• •Sialogogue activity. Physalaemin is a notably potent stimulant of salivary secretion; its action on electrolyte excretion by the mandibular and sublingual salivary glands is a classic demonstration of tachykinin (PMID: 7169058, PMID: 6294828) physiology Pflugers Arch, 1979.
• •Smooth-muscle contraction. Contractile responses to physalaemin have been characterized in gastrointestinal preparations such as the rat esophagus, consistent with NK1-mediated motility effects Eur J Pharmacol, 2010.
• •Oncology relevance. Physalaemin-like immunoreactivity and tachykinin (PMID: 7169058, PMID: 6294828) biology were reported in human small-cell lung carcinoma, linking the amphibian peptide's pharmacology to mammalian tumor models Science, 1983.
• •Immune effects. The tachykinins neurokinin A and physalaemin were shown to stimulate murine thymocyte proliferation, an early indication of tachykinin–immune crosstalk Int Arch Allergy Appl Immunol, 1989.
• •Epithelial ion transport. Physalaemin modulates ionic transport across frog skin, a tractable native-tissue system for studying tachykinin (PMID: 7169058, PMID: 6294828) effects on epithelia Arch Physiol Biochem, 1998.

These are research findings in defined assay systems, reported only to characterize the reagent's documented experimental behavior.

Why physalaemin is a useful research reagent

For tachykinin (PMID: 7169058, PMID: 6294828) and NK1 receptor researchers, physalaemin offers several enduring advantages:

1. Reference NK1 agonist. Decades of pharmacology make it a well-characterized comparator to substance P.

2. Radioligand heritage. [³H]physalaemin established it as a binding-site probe J Neurosci, 1985.

3. Structural model. Its membrane-associated conformation informs tachykinin–GPCR interaction studies Biopolymers, 2011.

4. Cross-system breadth. Documented salivary, smooth-muscle, epithelial, immune, and tumor-model effects support diverse in-vitro designs.

It pairs naturally with other vasoactive and kinin research peptides in comparative panels.

Handling and reconstitution notes

Synthetic physalaemin supplied for research is typically lyophilized and, as a C-terminally amidated undecapeptide, is generally water-soluble. Standard practice applies: review the certificate of analysis for identity and purity, confirm purity by HPLC and mass spectrometry, and select a vehicle following a solubility guide. Document reconstitution carefully per standard reconstitution practice, and apply ordinary supplier-evaluation diligence when sourcing material.

Summary

Physalaemin is a classic 11-residue amphibian tachykinin (PMID: 7169058, PMID: 6294828) bearing the conserved Phe-Xaa-Gly-Leu-Met-NH₂ motif and acting as a potent NK1 receptor agonist. With a long history as a radioligand and reference agonist, a well-studied membrane-associated conformation, and documented sialogogue, smooth-muscle, epithelial, immune, and tumor-model activity, it remains a foundational and mechanistically rich reagent for tachykinin (PMID: 7169058, PMID: 6294828) and NK1 receptor research.

Structural determinants of NK1 selectivity

Physalaemin's potent NK1 selectivity is encoded primarily in residues 1–6. The C-terminal Phe-Gly-Leu-Met-NH₂ pentapeptide is the universal tachykinin (PMID: 7169058, PMID: 6294828) pharmacophore, while the distinctive N-terminal sequence (pyroGlu-Ala-Asp-Pro-Asn-Lys-) positions physalaemin as a high-affinity NK1 ligand. SAR studies using physalaemin analogues and truncated fragments demonstrated that:

• •The pyroglutamyl N-terminus is not essential for receptor binding but contributes to metabolic stability and resistance to N-terminal exopeptidases
• •Asp at position 3 contributes to NK1 over NK2 preference — substituting Glu reduces but does not abolish NK1 selectivity
• •The undecapeptide length supports an extended conformation in aqueous solution with a C-terminal helical turn at residues 7–11 that maps onto the NK1 orthosteric pocket

NMR and molecular dynamics studies in membrane-mimicking solvents (TFE/water, DMSO/water, SDS micelles) show physalaemin adopts a curved, partially helical structure in which the Pro-containing region provides a kink that brings the N- and C-termini into proximity — a conformation consistent with receptor-bound states derived from GPCR homology models and later confirmed by NK1 crystal structures complexed with substance P analogues Biopolymers, 2011.

Physalaemin vs. substance P in NK1 receptor research

Physalaemin and substance P (SP) are both classic NK1 agonists with overlapping but distinct pharmacological profiles:

The practical consequence for research design: physalaemin's higher metabolic stability means it produces longer-lasting contractile responses in isolated tissue preparations — an advantage when characterizing slow-onset antagonists or when sustained receptor stimulation is desired. Its historical status as a radioligand (in the [³H]physalaemin era) also provides a large body of published binding data for cross-study comparisons.

In vitro model applications

Salivary gland models. Physalaemin has well-characterized sialogogue activity — it stimulates amylase secretion and acinar cell exocytosis in parotid and submandibular gland preparations, mediated via NK1 on parasympathetic postganglionic nerve terminals and on acinar cells directly. These preparations (isolated rat submandibular gland, dispersed parotid acini) provide a specific and sensitive functional readout for NK1 activation Eur J Pharmacol, 1985.

Smooth-muscle pharmacology. Guinea-pig ileum (GPI) longitudinal muscle-myenteric plexus preparations contract dose-dependently to physalaemin, providing a classical bioassay endpoint. Physalaemin is particularly useful in GPI preparations because its lower NK2 activity reduces the risk of misattributing NK2-mediated contractions (from residual NKA in the preparation) to NK1. Concentration range: 0.1 nM – 100 nM.

Cardiovascular models. Physalaemin produces NK1-mediated vasodilation and hypotension in vivo (rat pithed preparation, isolated perfused mesenteric bed), which have been used to validate NK1 antagonist potency in cardiovascular contexts. Its potency in these models is 2–5-fold greater than SP, making it useful for antagonist IC₅₀ measurements where a more sensitive agonist challenge is desirable.

Neuroinflammation and pain models. Intrathecal physalaemin administration produces NK1-dependent pain behavior (flinching, licking) in rodents and has been used in models of central sensitization and wind-up. In dorsal horn preparations, it enhances wide-dynamic-range neuron firing at 10–100 nM concentrations — effects blocked by NK1 antagonists such as CP-96,345 Eur J Pharmacol, 1991.

Radioligand heritage and modern applications

Physalaemin's history as a radioligand — [³H]physalaemin was introduced in 1985 to characterize substance P binding sites in brain membranes J Neurosci, 1985 — predates most modern NK1-selective radioligands. While [¹²⁵I]SP and modern fluorescence-based binding assays have largely replaced [³H]physalaemin in routine screening, the historical binding data generated with physalaemin remains a reference point for NK1 receptor density measurements in CNS tissue and for cross-referencing modern recombinant-receptor assays against in vivo pharmacology.

In contemporary drug discovery, physalaemin appears in selectivity panels for NK1 antagonists — particularly those targeting CNS indications — where its potency, established pharmacology, and commercial availability as a synthetic reagent make it a practical reference agonist across multiple assay formats (binding, Ca²⁺ mobilization, β-arrestin recruitment).

---

This article is provided for informational and research purposes only. Peptides and related compounds described here are research-use-only (RUO) laboratory reagents and are not intended for human or veterinary diagnostic, therapeutic, or other use. No statement herein constitutes medical advice or a claim of safety or efficacy.